lidocaine has been researched along with Impotence in 12 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lidocaine 1% can be safely and usefully combined with intracorporeal prostaglandin E1 in the treatment of erectile dysfunction with alleviation of pain and enhancement of erectile effect." | 9.08 | Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. ( Kattan, S, 1995) |
| "Lidocaine 1% can be safely and usefully combined with intracorporeal prostaglandin E1 in the treatment of erectile dysfunction with alleviation of pain and enhancement of erectile effect." | 5.08 | Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. ( Kattan, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shafik, A | 1 |
| Shafik, AA | 1 |
| Shafik, IA | 1 |
| El Sibai, O | 1 |
| Angeloni, NL | 1 |
| Bond, CW | 1 |
| Monsivais, D | 1 |
| Tang, Y | 1 |
| Podlasek, CA | 1 |
| Xin, ZC | 1 |
| Zhu, YC | 1 |
| Yuan, YM | 1 |
| Cui, WS | 1 |
| Jin, Z | 1 |
| Li, WR | 1 |
| Liu, T | 1 |
| Henry, R | 1 |
| Morales, A | 1 |
| Hsu, GL | 1 |
| Hsieh, CH | 1 |
| Wen, HS | 1 |
| Chen, SC | 1 |
| Chen, YC | 1 |
| Liu, LJ | 1 |
| Mok, MS | 1 |
| Wu, CH | 1 |
| Kattan, S | 1 |
| Dos Reis, JM | 1 |
| Glina, S | 1 |
| Da Silva, MF | 1 |
| Furlan, V | 1 |
| Palmer, JM | 1 |
| Link, D | 1 |
| Schouman, M | 1 |
| Lacroix, P | 1 |
| Amer, M | 1 |
| Fein, RL | 1 |
| Reiss, HF | 1 |
| Henriet, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)[NCT00556478] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Summary of mean IELT at Baseline and at month 3 during double-blind treatment (NCT00556478)
Timeframe: 3 months
| Intervention | Seconds (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 140.964 |
| Double-Blind Placebo / Open-Label Active | 49.615 |
"To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by:~• change in mean IELT from baseline to during the 3 month double-blind treatment~Results provide are ratio (over the 3 months/baseline)." (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | ratio (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 4.607 |
| Double-Blind Placebo / Open-Label Active | 1.505 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 1.~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 1 month
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Distress | Sexual satisfaction | |
| Double-Blind Active / Open-Label Active | 5.7 | 2.5 | 5.1 |
| Double-Blind Placebo / Open-Label Active | 1.3 | 0.6 | 1.8 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 2~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 2 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Control | Satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 6.5 | 5.8 | 2.9 |
| Double-Blind Placebo / Open-Label Active | 1.4 | 1.3 | 0.7 |
"To Evaluate Efficacy of Treatment With PSD502 Compared With Placebo in Subjects With PE as measured by:~• changes in all 3 IPE domains from baseline to month 3~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Sexual satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 7.2 | 6.6 | 3.5 |
| Double-Blind Placebo / Open-Label Active | 2.2 | 2.1 | 0.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the partner PEP at month 3. Proportion of partners with at least a 1 point category improvement in partner PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of partners (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 68.9 | 64.9 | 62.8 | 66.9 |
| Double-Blind Placebo / Open-Label Active | 40.8 | 50.0 | 32.9 | 50.0 |
Percentage of subjects with mean IELT > 1 minute and >2 minutes during the 3 months of double-blind treatment as measured by the proportion of subjects (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| IELT > 1 minute | IELT > 2 minutes | |
| Double-Blind Active / Open-Label Active | 80.2 | 57.5 |
| Double-Blind Placebo / Open-Label Active | 37.8 | 14.6 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 1. Percentage of subjects with at least a 1 point category improvement in subject PEP domain scores at month 1. (NCT00556478)
Timeframe: 1 month
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 59.6 | 63.4 | 62.7 | 72.0 |
| Double-Blind Placebo / Open-Label Active | 23.5 | 27.2 | 33.3 | 51.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 2. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 2. (NCT00556478)
Timeframe: 2 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 67.5 | 70.1 | 69.4 | 75.8 |
| Double-Blind Placebo / Open-Label Active | 24.7 | 33.8 | 27.3 | 42.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 3. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 72.4 | 76.9 | 73.7 | 77.6 |
| Double-Blind Placebo / Open-Label Active | 24.1 | 36.7 | 36.7 | 59.5 |
1 review available for lidocaine and Impotence
| Article | Year |
|---|---|
Current therapeutic strategies for premature ejaculation and future perspectives.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antidepressive Agents; Drug Combinations; Ejaculat | 2011 |
2 trials available for lidocaine and Impotence
| Article | Year |
|---|---|
Percutaneous perineal electrostimulation induces erection: clinical significance in patients with spinal cord injury and erectile dysfunction.
Topics: Adult; Analysis of Variance; Anesthetics, Local; Electric Stimulation; Erectile Dysfunction; Humans; | 2008 |
Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence.
Topics: Adult; Alprostadil; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Erectile Dys | 1995 |
9 other studies available for lidocaine and Impotence
| Article | Year |
|---|---|
The role of hedgehog-interacting protein in maintaining cavernous nerve integrity and adult penile morphology.
Topics: Animals; Apoptosis; Erectile Dysfunction; Hedgehog Proteins; Lidocaine; Male; Nitric Oxide; Penis; R | 2009 |
Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study.
Topics: Administration, Topical; Adult; Aerosols; Aged; Anesthetics, Local; Ejaculation; Erectile Dysfunctio | 2003 |
Outpatient penile implantation with the patient under a novel method of crural block.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Local; Erectile Dysfunction; Humans; Lidoca | 2004 |
Penile prosthesis surgery with the patient under local regional anesthesia.
Topics: Ambulatory Surgical Procedures; Anesthesia, Local; Erectile Dysfunction; Humans; Lidocaine; Male; Mi | 1993 |
Impotence following anesthesia for elective circumcision.
Topics: Adult; Anesthesia, Local; Blood Vessels; Circumcision, Male; Epithelium; Erectile Dysfunction; Human | 1979 |
Suppression of prostaglandin E1-induced pain by dilution of the drug with lidocaine before intracavernous injection.
Topics: Alprostadil; Erectile Dysfunction; Humans; Injections; Lidocaine; Male; Pain; Penis | 1992 |
Duraphase penile prosthesis dorsal approach using local anesthesia.
Topics: Anesthesia, Local; Bupivacaine; Erectile Dysfunction; Humans; Lidocaine; Male; Penile Prosthesis; Pe | 1991 |
Re: Penile pharmacocavernosography and cavernosometry in the evaluation of impotence.
Topics: Anesthesia, Local; Erectile Dysfunction; Humans; Lidocaine; Male; Penile Erection; Penis; Radiograph | 1989 |
[Priapism and impotence. Argument for early incision of the corpus cavernosum].
Topics: Chymotrypsin; Cystoscopy; Dextrans; Erectile Dysfunction; Hematoma; Hematuria; Heparin; Humans; Kidn | 1968 |